Risk of Nerve Damage After Administration of Local Anesthesia

Cleveland Dental Institute

Status and phase: Enrolling; Phase 1

Conditions: Inferior Alveolar Nerve Injuries

Treatments: Drug: 4% Articaine with 1:200,000 epinephrine; Drug: 2% lidocaine with 1:100,000 epinephrine

Study type: Interventional

Funder types: Other

Identifiers

NCT06564987

CDIOS0005

Details and patient eligibility

About

This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with age between 18-55 years old
• Patients need IANB
• healthy patient

Exclusion criteria

• medical conditions
• allergies
• medications
• pregnancy and breastfeeding
• inability to provide informed consent
• specific dental or medical history.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

80 participants in 2 patient groups

Articaine

Experimental group

Description:

Inferior Alveolar Nerve block using Articaine 4% with 1:200,000 epinephrine local anesthetic

Treatment:

Drug: 4% Articaine with 1:200,000 epinephrine

Lidocaine

Active Comparator group

Description:

Inferior Alveolar Nerve block using 2% lidocaine with 1:100,000 epinephrine local anesthetic

Treatment:

Drug: 2% lidocaine with 1:100,000 epinephrine